

***TP53* Abnormalities are frequent and early events in the sequential pathogenesis of gallbladder carcinoma[§]**

Mauricio Moreno;¹ Fernando Pimentel;² Adi F Gazdar;³ Ignacio I. Wistuba;⁴ Juan F. Miquel¹

Abstract

Background: Gallbladder carcinoma (GBC) is a frequent neoplasm in Hispanic and native American populations. GBC is preceded by gallstones, chronic cholecystitis and dysplastic changes of the gallbladder epithelium. The knowledge of the molecular events involved in its pathogenesis is scarce. **Aims:** We investigated the role of *TP53* inactivation in the sequential pathogenesis of GBC. **Methods:** Invasive tumor-, dysplastic- and histologically normal GB epithelial-cells were obtained from archival formalin-fixed tissues from GBC and GB from gallstone patients without GBC. Normal GB epithelia from 5 non-gallstone specimens were also studied. DNA extracted was examined for loss of heterozygosity (LOH) using 2 microsatellite markers and for *TP53* mutations at exons 5 to 8. **Results:** GBCs demonstrated a high frequency of LOH (81%) and mutation (67%), and both abnormalities indicating gene inactivation were detected in 52%. Similar frequency of

TP53 abnormalities and gene inactivation (38%) were detected in their accompanying normal and dysplastic epithelia. Noteworthy, one third of normal and dysplastic epithelia obtained from GBs of gallstone patients without GBC demonstrated either *TP53* allele loss or mutation, but gene inactivation was less frequent (11%). Most mutations affected exons 5 and 7, and they were more frequently missense point mutations. The same *TP53* mutation was detected in only a subset (27%) of comparisons between non-malignant epithelia adjacent to GBCs, indicating that *TP53* mutation occurs independently at several epithelial foci. **Conclusions:** These findings indicate that *TP53* abnormalities are early and frequent events in the pathogenesis of GBC, starting from chronic cholecystitis.

Key words: Mutations, loss of heterozygosity, microdissection, preneoplastic lesions, gallbladder.

Introduction

Gallbladder carcinoma (GBC) is a relatively uncommon neoplasm in the world, but there is considerable geographic variation in its incidence.¹ In Hispanic populations with native American background, GBC is one of the most frequent neoplasms, where it is the leading cause of cancer deaths in females.¹ Although GBC has been associated with genetic and environmental risk factors, there is limited information about the molecular changes involved in its pathogenesis.² It has been claimed that cholesterol gallstone disease and subsequent chronic aseptic cholecystitis is the most relevant risk factor for GBC.¹³ In fact, prevalence of GBC correlates with the prevalence of gallstone disease in different populations.¹ As with other epithelial neoplasms, it has been well established that invasive GBC is preceded by preneoplastic lesions, including dysplastic changes of the gallbladder epithelium.⁴

Multiple genetic changes are associated with the development of many human cancers, and molecular studies in several neoplasms have demonstrated their association with the activation of dominant oncogenes and inactivation of recessive tumor suppressor genes. The *TP53* tu-

¹ Department of Gastroenterology. Pontificia Universidad Católica de Chile, P.O. Box 114-D Santiago, Chile.

² Department of Surgery. Pontificia Universidad Católica de Chile, P.O. Box 114-D Santiago, Chile.

³ Hammon Center for Therapeutic and Oncology Research, UT Southwestern Medical Center, Dallas, TX 75390, USA.

⁴ Department of Pathology, MD Anderson Cancer Center, Houston, TX 77030, USA.

Address for correspondence:

Juan F. Miquel, MD

Department of Gastroenterology

Pontificia Universidad Católica de Chile

Marcoleta 367, Santiago-CHILE

ZIP code: 6513677

Tel 56-2-3543830

Fax 56-2-6397780

E-mail: jfmiquel@med.puc.cl

Abbreviations: GBC, gallbladder carcinoma; LOH, loss of heterozygosity; TSG, tumor suppressor gene.

[§] Supported by Grants FONDECYT (Fondo Nacional de Desarrollo Científico y Tecnológico) #1040820, #1971100, and # 1990489.

Manuscript received and accepted: 23 and 28 June, 2005.

mor suppressor gene, located on the short arm of the chromosome 17 (17p13.1), encodes a 53-kD nuclear phosphoprotein that acts as a "master" transcription factor.⁵ p53 is believed to play a major role in maintaining the integrity of the genome since loss of p53 function allows inappropriate survival of genetically damaged cells, leading to the evolution of a cancer cell.⁵ Mutations of the *TP53* gene are among the most frequent genetic alterations in human cancers and are thought to play a role in the pathogenesis of many malignancies.^{6,7} One copy of the chromosomal region 17p13.1 which houses *TP53* gene is frequently deleted, and subsequent mutational inactivation of the remaining allele occurs.⁷

As with several other human neoplasms, *TP53* mutations,⁸⁻¹⁴ allele loss^{1,15} and immunohistochemical protein over-expression¹⁶⁻²² have been reported as frequent events in advance GBC. Analyses of exon 5 to 8 of the *TP53* gene have demonstrated point mutations in 31 to 70% of gallbladder carcinomas, and no particular hot-spot has been identified so far.⁸⁻¹³ Our allelotyping studies on GBC have indicated that allelic loss or loss of heterozygosity (LOH) at the *TP53* locus is a frequent (91%) molecular change detected in this neoplasm.^{1,15} Although several studies have demonstrated that *TP53* mutation or allele loss are common events in advanced GBC, there is no study addressing both abnormalities responsible for the gene inactivation in GBC and in clinical steps preceding GBC, such as gallbladder epithelium from gallstone patients with chronic cholecystitis. Thus, the present study was undertaken to study the role of *TP53* gene inactivation abnormalities in the sequential pathogenesis of GBC by examining histologically normal gallbladder epithelia and preneoplastic lesions from gallstone patients without GBC, and in patients with invasive GBC.

Materials and methods

Archival Tumor Specimens. Formalin-fixed paraffin-embedded material from 30 surgically resected primary invasive gallbladder carcinomas was obtained from cholecystectomy specimens resected between 1996 and 2000 at the Catholic University Medical School Hospital, Santiago, Chile, as part of an Institutional Review Board approved study. The patients consisted of 20 women and 10 men ranging in age from 48-79 years (mean age, 57 years). Seven (23%) were well differentiated, ten (33%) were moderately differentiated, and 13 (43%) were poorly differentiated tubulo-papillary adenocarcinomas. The majority of the tumors were advanced GBCs (25 cases, 83%) with invasion of the gallbladder serosa; the remaining were early GBCs, with invasion of the submucosa (3 cases, 10%) or muscularis propria (2 cases, 7%) of the gallbladder.

Normal Epithelium and Preneoplastic Lesions Accompanying Gallbladder Cancer. Twenty-three histologically discrete foci of non-invasive gallbladder epithe-

lia were identified adjacent to 16 GBCs, each consisting of at least 1,000 cells. These included 7 histologically normal epithelia and 16 dysplasias. The dysplastic lesions were scored using published criteria for their histopathological identification in the gallbladder epithelium.⁴

Normal Epithelium and Preneoplastic Lesions from Patients without Gallbladder Cancer. Histologically normal and dysplastic epithelia from 61 gallbladder specimens obtained from gallstone patients with chronic cholecystitis in the absence of GBC were also selected. These included 39 gallbladder specimens with discrete epithelial dysplastic foci, and 22 with histologically normal epithelia. In the dysplastic and non-dysplastic cases, the whole gallbladder specimen was histologically examined to rule out the presence of invasive carcinoma and dysplasia, respectively. In addition, five normal gallbladder specimens were obtained from non-gallstone patients and their histologically normal epithelium was examined.

Microdissection and DNA Extraction. Serial 5 μ m-sections were cut from archival, formalin-fixed, paraffin embedded tissue. All slides were stained with hematoxylin-eosin, and one of the slides was coverslipped. The coverslipped slide was used as a guide to localize regions of interest for microdissection for the other slide. Laser capture microdissection and DNA extraction were performed from precisely identified areas of stromal lymphocytes, invasive carcinoma and dysplastic or normal epithelia from gallbladder specimens as previously described from non-coverslipped hematoxylin-eosin stained slides.²³

Loss of Heterozygosity Analysis of *TP53* Locus. Extracted DNAs were utilized for loss of heterozygosity (LOH) analysis at *TP53* locus (17p13.1) using two polymorphic microsatellite markers, a dinucleotide CA repeat flanking the gene²⁴ and a pentanucleotide AAAAT repeat located in intron 1 of the gene.²⁵ A two-round PCR strategy (multiplex PCR followed by uniplex PCR) was utilized to amplify each marker, as described previously.²³ The final product was separated on a 6% denaturing polyacrylamide gel and subjected to autoradiography. LOH was scored by visual detection of complete absence of one allele of informative cases (*Figure 1*).

***TP53* Mutation Analysis.** Mutations were examined in exons 5 to 8 which harbor 87% of gene mutations reported for *TP53* in human neoplasms.⁶ These exons encode for the critical region which determined p53 conformation, specific binding to DNA consensus sequences, and sequence-specific transcriptional activity which may be essential for growth suppression.⁶ We screened for mutations using nested PCR methodology and non-isotopic RNase cleavage assay (NIRCATM) Mismatch Detect IITM kit (Ambion, Austin, TX, US), followed by direct sequencing of both strands of abnormal bands at the NIRCA assay (*Figures 2A, B*). Specificity of identified point mutations were always confirmed by a second sequencing analysis starting from the original DNA samples of tu-




Figure 1. Representative autoradiographs of microsatellite analysis for allele loss using the pentanucleotide repeat on the *TP53* locus in gallbladder specimens. *L*, lymphocytes; *NE*, normal epithelium; *D*, dysplasia; and, *T*, tumor. Horizontal bars on the left of each autoradiograph indicate the main allelic band. Closed arrowheads indicate allele losses.




Figure 2A and B. Representative example of the PCR-based *TP53* mutations screening method (exons 5 to 8), using PCR amplification, non-isotopic RNase cleavage assay and agarose gel electrophoresis (four gels, Panel A), followed by sequencing (Panel B). Panel A, Open arrowheads indicate cases with abnormal bands selected for sequencing analysis. *M*, size marker; *C*, positive controls (lung cancer cell lines having *TP53* mutations); *S*, negative controls, stromal cells; and, *T*, tumor cases. Panel B, sequencing of exon 5 showing a point mutation in codon 164 in invasive carcinoma sample.

mor- or epithelial-cells and corresponding stromal cells. The NIRCA™ technique has been adapted from a screening method based on the observation that RNase A is frequently able to cleave a single unpaired base (mismatch) in an RNA probe hybridized to an experimental target containing a point mutation.^{26,27} Briefly, in the NIRCA™ procedure the target substrates for RNase digestions are RNA/RNA duplexes made by hybridizing complementary wild and experimental transcripts. The outline of the NIRCA™ procedure can be broken down in the five following steps: 1) PCR amplification of experimental and wild type control DNA sequences. 2) Transcription of both strands of experimental and wild type PCR product. 3) Hybridization of complementary experimental and wild type transcripts. 4) Digestion of RNA duplexes with RNases (RNase 1, RNase T1 and RNase A). 5) Separations of digestion products by gel electrophoresis in agarose. Primers and PCR conditions to amplify exons 5 to 8 (step 1) from formalin fixed and paraffin embedded tissues have been previously published by some of us.²⁸ Step 2 and 5 were performed according to manufacturer's conditions (Mismatch Detect IITM kit, Ambion, Austin, TX, US). The corresponding positive (lung cancer cell

lines H2106, H23, H460) and negative (normal lymphocytes) controls were included in the analysis for each exon. NIRCATM assay was able to identify point mutations in all cell lines in different experiments and were consistently negative for mutations in negative control samples (stromal lymphocytes), showing a high sensitivity and specificity.

Data Analysis. Statistical analysis was performed using chi-square and Fisher Exact tests. The cumulative binomial test was used to examine the likelihood that the occurrence of a particular event (loss of the same allele in the invasive carcinoma and an associated epithelial sample) occurs at a particular probability when observed in repeated trials. When the results are compared with a chance occurrence or nonoccurrence, the particular probability of comparison is 0.5. Probability values of $P < 0.05$ were regarded as statistically significant.

Results

***TP53* Abnormalities in Invasive GBC.** LOH at the *TP53* locus using two microsatellite markers (81%), and gene mutation at exons 5 to 8 (67%) were frequently de-

Table I. Frequency of *TP53* abnormalities (LOH, mutation and any change) and gene inactivation in the sequential pathogenesis of GBC.

Histology N (%) ¹	Loss of Heterozygosity N (%) ²	Mutation N (%) ³	Any Change N (%) ⁴	Gene Inactivation
Normal Gallbladder	0/4	0/5	0/4	0/4
Chronic Cholecystitis Specimens ⁵	16/46 (35%)	15/61 (25%)	26/46 (57%)	5/46 (11%)
Normal Epithelium	6/17 (35%)	6/22 (27%)	11/17 (65%)	1/17 (6%)
Dysplasia	10/29 (35%)	9/39 (23%)	15/29 (52%)	4/29 (14%)
Cancer Specimens ⁶	28/34 (82%)	35/53 (66%)	32/34 (96%)	16/34 (47%)
Normal Epithelium	2/3 (67%)	4/7 (57%)	3/3 (100%)	1/3 (33%)
Dysplasia	9/10 (90%)	11/16 (69%)	9/10 (90%)	4/10 (40%)
Invasive Carcinoma	17/21 (81%)	20/30 (67%)	20/21 (95%)	11/21 (52%)
Total	44/84 (52%)	50/119 (42%)	58/84 (69%)	21/84 (25%)

¹ Cases having LOH by informative cases at any of the two microsatellite markers examined. ² Cases demonstrating any gene mutation at exon 5 to 8. ³ Cases with any gene abnormality examined for both LOH and mutation. ⁴ Cases showing both non-silent mutations and LOH at the *TP53* locus. ⁵ Sum of samples obtained from chronic cholecystitis specimens, including normal epithelia and dysplasias without cancer. ⁶ Sum of samples obtained from GBC specimens, including normal epithelium, dysplasia and invasive carcinoma.

tected in invasive GBC (*Table I*). Any *TP53* abnormality was found in most (95%) tumors. GBC demonstrated a high frequency of multiple *TP53* mutations in exons 5 to 8, with 15 out of 20 (75%) tumors having more than one mutation and the mean number of mutations detected by case was 3 (range 1 to 5) (data not shown). As *TP53* allele loss and mutation analyses were performed in the same tumor samples, we examined in GBCs the frequency of gene inactivation defined by the presence of both abnormalities in the same tumor specimen (*Table I*). Twenty-one GBCs examined for mutation were informative for LOH at any microsatellite marker tested, and of those 11 (52%) tumors demonstrated both *TP53* changes. For *TP53* inactivation analysis, only mutations producing amino acid change (nonsense, frame-shift and missense) were considered. No correlation between *TP53* changes and clinico-pathological features of GBC was detected (data not shown).

***TP53* Abnormalities in Preneoplastic and Histologically Normal Gallbladder Epithelia.** To investigate the role of *TP53* abnormalities in the sequential pathogenesis of GBC, histologically normal and dysplastic epithelia accompanying GBCs and in chronic cholecystitis from gallstone patients without GBC were examined. Although a limited number of histologically normal epithelia and dysplasias accompanying invasive GBC were studied, the majority of those specimens demonstrated a high incidence of both allele loss (normal epithelium 67%, and dysplasia 90%) and mutation (normal epithelium 57%, and dysplasia 69%) (*Table I*). However, all the epithelial specimens studied for allele loss and mutation were obtained exclusively from invasive GBC having the corresponding *TP53* changes. Somewhat striking, approximately one third of the histologically normal and dysplastic epithelia samples obtained from gallstone patients with chronic cholecystitis and without GBC demonstrated either *TP53* allele loss (normal epithelium and dysplasia 35%) or mutation (normal epithelium 27%, and dysplasia 23%) (*Table I*). While any *TP53* change was found in al-

most all normal and dysplastic samples associated to GBCs, they were detected in nearly half of the epithelia from chronic cholecystitis in the absence of GBC. In contrast, normal epithelium obtained from five histologically normal gallbladders from patients without gallstones did not show any *TP53* change (*Table I*).

A progression in the number of *TP53* mutations by sample according with increasing histopathological grade was observed (data not shown). As their corresponding tumors, histologically normal and dysplastic epithelia associated to GBC demonstrated frequently multiple *TP53* mutations. While normal epithelium from chronic cholecystitis presented a single mutation for case, dysplasias obtained from the same type of non-malignant gallbladder specimens demonstrated intermediate number (mean 1.69; range 1 to 2) of mutations.

Gene inactivation phenomenon by examination of both *TP53* abnormalities was more frequently detected in histologically normal and dysplastic epithelia from gallbladder specimens with invasive GBC than those obtained from chronic cholecystitis (*Table I*). While 1 out of 3 (33%) normal and 4 out of 10 (40%) dysplastic epithelia accompanying GBCs demonstrated *TP53* inactivation, this phenomenon was present in 1 out of 17 (6%) normal epithelium and 4 out of 29 (14%) dysplasias obtained from chronic cholecystitis without GBC.

***TP53* Mutation Pattern in the Pathogenesis of GBC.** The mutation distribution by exons and codons detected in invasive GBC, preneoplastic lesions and histologically normal epithelium is shown in *figure 3*. Overall, ninety-five *TP53* mutations were detected in GBC and epithelial samples, and tumor and dysplastic samples demonstrated at very high frequencies more than one mutation. Mutations on tumors (17 out of 46 mutations; 37%) and their accompanying dysplastic and normal epithelia (18 out of 30; 60%) affected more frequently to exon 5, and those detected in epithelial samples obtained from chronic cholecystitis specimens (10 out of 19; 53%) were more frequently found in exon 7.

The distribution of mutations by codon showed no particular hot-spot in gallbladder samples; however, the codons showing more frequently mutations were 144 (N = 11) and 248 (N = 6) (Figure 3).

Twenty-five percent (24 out of 95) of the *TP53* mutations detected were silent mutations (Figure 4, A), and they were not detected in the corresponding stromal tissue obtained from the same patient confirming that they were not polymorphism. Nearly half of the mutations detected in normal (3 out of 6; 50%) and dysplastic (6 out of 13; 46%) epithelia from chronic cholecystitis specimens were silent. These frequencies were significantly higher ($P < 0.015$) than the incidences of silent mutations in tumors (12 out of 46; 26%) and their accompanying normal (1 out of 7; 14%) and dysplastic (2 out of 23; 9%) epithelia. Among the mutations producing amino acid change (N = 71 mutations), missense point mutations (N = 57; 80%) were the commonest observed (Figure 4, A). Nonsense point mutations were less frequent (N = 13; 18%), deletion producing frame-shift mutation were extremely rare (N = 1; 2%), and no insertion was detected.

By far, transition type of *TP53* point mutations (77 out of 94; 82%) showed the greatest incidence in GBCs, dysplastic lesions and normal epithelia. It was the only type detected in normal and dysplastic samples obtained from

chronic cholecystitis. Of great interest, transitions G:C>A:T were the commonest mutation detected (68 out of 94; 72%) in our study, followed by A:T>G:C change (9 out of 94; 10%; (Figure 4, B).

***TP53* Allele Specific Loss and Mutation.** Previous studies in GBC and other neoplasms demonstrated that at any one locus, loss of parental alleles was not random, and that there was a strong tendency for the identical allele to be lost in all non-neoplastic and neoplastic foci examined.^{15,29} We refer to this phenomenon as allele specific loss. We determined the frequency of allele specific loss in the 16 epithelial and tumor foci demonstrating one or more sites of allelic loss in 8 GBC cases. The same parental allele was lost in all 13 comparisons involving both microsatellite markers examined at the *TP53* locus. The possibility that this occurred by chance alone is remote as tested by the cumulative binomial test ($P = 0.000012$). Then, we examined the *TP53* mutation pattern to mark the different foci of cancer and accompanying gallbladder epithelia in individual cases. Of interest, the same *TP53* mutation compared to the corresponding tumor was detected in only 4 out of 11 (27%) normal and dysplastic epithelia. Thus, while the allele specific loss phenomenon was detected comparing our invasive tumors and their corresponding normal and dysplastic epithelia, they did not demonstrate *TP53* specific mutations.

***TP53* Abnormality Patterns.** To determine the sequence of changes involved in the inactivation of *TP53* in the pathogenesis of GBC, we analyzed the pattern of allele loss and mutation detected in tumors and normal and dysplastic epithelia obtained from malignant and non-malignant gallbladder specimens. Seventy-two tumor and epithelial samples informative for any microsatellite marker used to test LOH at *TP53* locus were examined for gene mutations, and the 4 possible patterns of *TP53* abnormalities (I, no change; II, only LOH; III, only mutation; and, IV, LOH and mutation) were detected. The relationship between histopathological diagnoses and patterns of *TP53* inactivation is displayed in figure 5. Of interest, pattern II (only LOH) was more frequently detected than pattern III (only mutation) in overall samples (22/52,




Figure 3. *TP53* point mutation (vertical lines) distribution (N = 94) by codons in GBC pathogenesis. Boxes indicate exons. The distribution of mutations by codon showed no particular hot-spot in gallbladder samples; however, the codons showing more frequently mutations were 144 (N = 11) and 248 (N = 6).




Figure 4A and B. Panel A, *TP53* point mutation (N = 94) type frequencies in GBC pathogenesis. Panel B, *TP53* mutational spectrum in GBC pathogenesis.




Figure 5. Patterns of *TP53* abnormalities (LOH and non-silent mutation) observed in 52 non-malignant and cancer gallbladder specimens. Relationship between histological categories and patterns of *TP53* abnormalities. Normal and dysplastic epithelia from non-malignant gallbladder specimens were obtained from chronic cholecystitis. Gene inactivation (pattern IV) is seen mostly in cancer specimens. Note that pattern II (only LOH) was more frequently detected than pattern III (only mutation) in overall samples, tumors and epithelia obtained from chronic cholecystitis.

42%, vs 11/52, 11%), tumors (7/20, 35%, vs 4/20, 20%) and epithelia obtained from malignant and non-malignant specimens (15/32, 47%, vs 7/32, 22%). Statistically significant differences were detected only when patterns of overall and epithelial samples were compared ($P = 0.017$, and $P = 0.39$, respectively). For this type of analysis, only mutations producing amino acid (non-silent mutations) changes were considered.

Discussion

The presence of a single *TP53* abnormality (LOH or point mutation) was detected in the majority of GBCs and in nearly half of them demonstrated both changes in the same sample consistent with inactivation of this tumor suppressor gene. Our data are in agreement with the high frequency of *TP53* abnormalities previously reported by us and others in GBC obtained from patients from Chile¹³⁻¹⁵ and elsewhere.⁸⁻¹³ However, there is no study addressing both abnormalities responsible for the *TP53* inactivation in invasive tumors and epithelia involved in the sequential pathogenesis of this highly malignant tumor.

In several neoplasms it has been established that multiple sequential genetic changes are associated with the development of invasive tumors. To investigate the role of *TP53* abnormalities in the sequential pathogenesis of GBC, histologically normal and dysplastic epithelia obtained from GBC and also from chronic cholecystitis gallbladder specimens obtained from gallstone patients without GBC were examined. Although a limited number of epithelial samples accompanying invasive tumors were studied, our finding of high frequencies of *TP53* abnormalities and gene inactivation in normal and dysplastic gallbladder epithelia associated to GBC confirmed that

this gene plays an important and early role in the sequential pathogenesis of this tumor. Although a high incidence of allelic loss at *TP53* locus occurring early during the sequential pathogenesis of GBC have been previously reported by us,¹⁵ this is the first report on *TP53* mutation and gene inactivation phenomenon in normal and dysplastic gallbladder epithelia obtained from GBC and chronic cholecystitis without GBC.

One of the most striking findings of our study is related to the analysis of *TP53* abnormalities in chronic cholecystitis epithelia obtained from gallstone patients without GBC. We demonstrate for the first time that approximately one third of the histologically normal and dysplastic epithelia obtained from those samples have either *TP53* allele loss or mutation, and any change was detected in nearly half of the samples. These findings lend stronger support to the view of *TP53* as an important and early event in gallbladder tumorigenesis. Moreover, normal epithelium obtained from 5 normal gallbladder specimens available to us without gallstones and inflammatory changes did not demonstrate any *TP53* abnormality. The development of epithelial cancers requires multiple mutations, and the stepwise accumulation of these mutations may represent an inherent mutator phenotype.³⁰ Thus, we speculate that is likely that those normal and dysplastic epithelia from chronic cholecystitis that have accumulated multiple mutations, including *TP53* abnormalities, are at higher risk for progression to GBC. The morphologically defined stages in which *TP53* mutation appears in the sequential development of other epithelial tumors have been established,⁶ and there are few examples of human tissues with frequent *TP53* mutation occurring in normal epithelium from patients without neoplasm.³¹⁻³³

Tumor suppressor genes are believed to be inactivated via a two-step process involving both alleles, including among other mechanism mutation, deletion and aberrant methylation. For *TP53*, one copy of the chromosomal region 17p13.1 is frequently deleted and mutational inactivation of the remaining allele occurs.⁷ By examining *TP53* locus allele loss and synchronic gene mutation in the same tumor and epithelium samples from malignant and non-malignant gallbladder specimens, we have provided for the first time data on the role of *TP53* inactivation phenomenon in the sequential pathogenesis of GBC. Interestingly, *TP53* inactivation was detected in nearly half of invasive tumors, and less frequently in dysplastic and normal epithelia accompanying GBCs. But such phenomenon was also detected in few normal (6%) and dysplastic (14%) epithelia from chronic cholecystitis specimens in the absence of tumor. We hypothesize that those normal and dysplastic lesions from gallstone patients having *TP53* inactivation are at higher risk for malignant transformation, and additional genetic change are required to progress to atypical lesion.

The sequence of molecular events involved in *TP53* inactivation has not been demonstrated for sporadic can-

cers. To determine the sequence of changes involved in the inactivation of *TP53* in the pathogenesis of GBC, we analyzed the pattern of allele loss and mutation detected in tumors and in normal and dysplastic epithelia obtained from malignant and non-malignant gallbladder specimens. Our finding of allele loss as a single *TP53* abnormality significantly more frequent compared to mutations in gallbladder tumor and epithelium samples suggest that allele loss at *TP53* locus may usually precede gene mutation. It may be possible that loss of one allele destabilizes and predisposes to mutation of the remaining allele.

The same parental *TP53* allele was lost in 100% of comparisons in non-neoplastic lesions as in the corresponding invasive carcinomas. We refer to this phenomenon as allele specific loss, and we have previously documented this phenomenon in GBC.^{15,29} Although the mechanism underlying allele specific loss remains unknown, recently we have demonstrated in GBC that this phenomenon is not related to a clonal relationship between the epithelial foci and their corresponding tumors using allele loss and microsatellite instability pattern analyses.²⁹ Of interest, the same *TP53* mutation was detected in only a subset (27%) of comparisons between non-malignant epithelia and corresponding GBCs, indicating that in gallbladder malignant transformation *TP53* mutations occur independently at several gallbladder epithelial foci, which are probably not clonally related which is also consistent with the LOH pattern described for GBC. These findings suggest that may be a strong field effect in gallbladder epithelium with chronic cholecystitis strongly predisposes to cancer.

The distribution of *TP53* mutations in our GBCs was similar to the one previously reported in this tumor type, being more frequent at exon 5.⁸⁻¹³ In our cases, the distribution of mutations by codon showed no particular hot-spot; however, codons 144 and 248 demonstrated more frequent mutations. Codon 248 is a hot-spot for mutations in human neoplasms (e.g., colon, skin, breast and lung), and encodes for an amino acid (Arg 248) which directly contact DNA and appears to be critical in stabilizing the protein-DNA interface.⁶ Most *TP53* mutations detected in GBC and gallbladder epithelia were single base substitutions or point mutations followed by missense mutations. This pattern of mutations is consistent with previous reported data on GBC.⁸⁻¹⁴ Of interest, most of our point mutations were transitions (82%), especially G:C>A:T (72%) changes. Similar mutation pattern can be found in 74 GBCs registered in the *TP53* mutation database maintained by the International Agency for Research on Cancer (IARC; version R9, July 2004; www.iarc.fr/p53).³⁴

Transitions have been reported as the most frequent base substitutions on *TP53* in human cancers³⁵. Frequent transitions, especially G to A and C to T at CpG sites, are features of mutational *TP53* spectra found in cancers not strongly linked to specific exogenous carcinogens⁶ and they are thought to be endogenous mutations caused

by spontaneous deamination of 5-methylcytosine.³⁶ Among 39 CpG dinucleotides in the human *TP53* coding region, codons 175, 213, 245, 248, 273 and 282 are known as hot spots resulting from endogenous mutational processes, and mutations at 4 of those codons were detected in our cases.⁷ Thus, we speculate that endogenous carcinogens associated to the chronic inflammation present in cholesterol gallstone patients might be one of the most relevant initiating steps in triggering gallbladder carcinogenesis. It has been suggested that long-standing chronic inflammatory process and their oxidative stress products may be associated to malignant transformation by generating frequent and early *TP53* changes in other gastrointestinal neoplasms, such as esophageal adenocarcinoma in Barrett's esophagus³⁷ and colon carcinoma in ulcerative colitis.³⁸ Of great interest, like our gallbladder specimens, in both ulcerative colitis (> 50%) and Barrett's esophagus (81%) their corresponding epithelia usually demonstrate frequent G:C>A:T transitions type of *TP53* mutations.³⁸

It has been established that aseptic or chemical chronic inflammation is involved in gallstone pathogenesis,³⁹ and that the presence of a lithogenic bile (cholesterol supersaturated bile) is able to generate a permanent aseptic inflammatory response in the gallbladder wall.^{39,40} This inflammatory phenomenon, probably associated to other carcinogenic stimulus, might contribute to the development of the sequential molecular and phenotypic abnormalities that ends in GBC. Our finding of *TP53* mutations early in the pathogenesis of GBC, including chronic cholecystitis, and the detection of a mutational pattern associated to endogenous mutational phenomenon suggests that chronic inflammatory process related to cholesterol gallstone may play an important role in *TP53* abnormalities and GBC development.

References

1. Lazcano-Ponce EC, Miquel JF, Munoz N, Herrero R, Ferrecio C, Wistuba, II, Alonso de Ruiz P, Aristi Urista G, Nervi F. Epidemiology and molecular pathology of gallbladder cancer. *CA Cancer J Clin* 2001; 51: 349-64.
2. Wistuba, II, Albores-Saavedra J. Genetic abnormalities involved in the pathogenesis of gallbladder carcinoma. *J Hepatobiliary Pancreat Surg* 1999; 6: 237-44.
3. Tang M, Baez S, Pruyas M, Diaz A, Calvo A, Riquelme E, Wistuba, II. Mitochondrial DNA mutation at the D310 (displacement loop) mononucleotide sequence in the pathogenesis of gallbladder carcinoma. *Clin Cancer Res* 2004; 10: 1041-6.
4. Albores-Saavedra J, Henson DE. *Tumors of gallbladder and extra-hepatic bile ducts*. Fascicle 23, third edit. Armed Forces Institute of Pathology, 2000.
5. Levine AJ. p53, the cellular gatekeeper for growth and division. *Cell* 1997; 88: 323-31.
6. Greenblatt MS, Bennett WP, Hollatein M, Harris CC. Mutations in the p53 tumor suppressor gene: clue to cancer etiology and molecular pathogenesis. *Cancer Res* 1994; 54: 4855-4878.
7. Harris CC. p53 Tumor suppressor gene: from the basic research laboratory to the clinic-an abridged historical perspective. *Carcinogenesis* 1996; 17: 1187-1198.

8. Hanada K, Itoh M, Fujii K, Tsuchida A, Ooishi H, Kajiyama G. K-ras and p53 mutations in stage I gallbladder carcinoma with an anomalous junction of the pancreaticobiliary duct. *Cancer* 1996; 77: 452-8.
9. Hanada K, Itoh M, Fujii K, Tsuchida A, Hirata M, Iwao T, Eguchi N, Sasaki T, Matsubara K, Kajiyama G. TP53 mutations in stage I gallbladder carcinoma with special attention to growth patterns. *Eur J Cancer* 1997; 33: 1136-40.
10. Fujii K, Yokozaki H, Yasui W, Kuniyasu H, Hirata M, Kajiyama G, Tahara E. High frequency of p53 gene mutation in adenocarcinomas of the gallbladder. *Cancer Epidemiol Biomarkers Prev* 1996; 5: 461-6.
11. Itoi T, Watanabe H, Yoshida M, Ajioka Y, Nishikura K, Saito T. Correlation of p53 protein expression with gene mutation in gallbladder carcinomas. *Pathol Int* 1997; 47: 525-30.
12. Jonas S, Springmeier G, Tauber R, Wiedenmann B, Gessner R, Kling N, Lobeck H, Fieger C, Bechstein WO, Neuhaus P. p53 hot-spot mutational analysis in advanced Western gallbladder carcinoma. *World J Surg* 1997; 21: 768-72.
13. Yokoyama N, Hitomi J, Watanabe H, Ajioka Y, Pruyas M, Serra I, Shirai Y, Hatakeyama K. Mutations of p53 in gallbladder carcinomas in high-incidence areas of Japan and Chile. *Cancer Epidemiol Biomarkers Prev* 1998; 7: 297-301.
14. Roa I, Melo A, Roa J, Araya J, Villaseca M, de Aretxabala X. [p53 gene mutation in gallbladder cancer]. *Rev Med Chil* 2000; 128: 251-8.
15. Wistuba II, Sugio I, Hung J, Kishimoto Y, Virmani AK, Roa I, Albores-Saavedra J, Gazdar AF. Allele specific mutations involved in the pathogenesis of endemic gallbladder carcinoma in Chile. *Cancer Res* 1995; 55: 2511-2515.
16. Kamel D, Paakko P, Nuorva K, Vahakangas K, Soini Y. p53 and c-erbB-2 protein expression in adenocarcinomas and epithelial dysplasias of the gall bladder. *J Pathol* 1993; 170: 67-72.
17. Teh M, Wee A, Raju GC. An immunohistochemical study of p53 protein in gallbladder and extrahepatic bile duct/ampullary carcinomas. *Cancer* 1994; 74: 1542-5.
18. Lee CS, Pirdas A. p53 protein immunoreactivity in cancers of the gallbladder, extrahepatic bile ducts and ampulla of Vater. *Pathology* 1995; 27: 117-20.
19. Diamantis I, Karamitopoulou E, Perentes E, Zimmermann A. p53 protein immunoreactivity in extrahepatic bile duct and gallbladder cancer: correlation with tumor grade and survival. *Hepatology* 1995; 22: 774-9.
20. Wistuba II, Gazdar AF, Roa I, Albores-Saavedra J. p53 protein overexpression in gallbladder carcinoma and its precursor lesions: an immunohistochemical study. *Hum Pathol* 1996; 27: 360-5.
21. Ajiki T, Onoyama H, Yamamoto M, Asaka K, Fujimori T, Maeda S, Saitoh Y. p53 protein expression and prognosis in gallbladder carcinoma and premalignant lesions. *Hepatogastroenterology* 1996; 43: 521-6.
22. Roa I, Villaseca M, Araya J, Roa J, de Aretxabala X, Melo A, Ibacache G. p53 tumour suppressor gene protein expression in early and advanced gallbladder carcinoma. *Histopathology* 1997; 31: 226-30.
23. Wistuba II, Behrens C, Milchgrub S, Virmani AK, Jagirdar J, Thomas B, Ioachim HL, Litzky LA, Brambilla EM, Minna JD, Gazdar AF. Comparison of molecular changes in lung cancers in HIV-positive and HIV- indeterminate subjects. *JAMA* 1998; 279: 1554-1559.
24. Jones MH, Nakamura Y. Detection of loss of heterozygosity at the human TP53 locus using a dinucleotide repeat polymorphism. *Genes Chromosom Cancer* 1992; 5: 89-90.
25. Futreal PA, Barrett JC, Wiseman RW. An Alu polymorphism intragenic to the PT53 gene. *Nucleic Acids Research* 1991; 19: 6977.
26. Myers RM, Larin Z, Maniatis T. Detection of single base substitutions by ribonuclease cleavage at mismatches in RNA:DNA duplexes. *Science* 1985; 230: 1242-6.
27. Winter E, Yamamoto F, Almoguera C, Peruchio M. A method to detect and characterize point mutations in transcribed genes: amplification and overexpression of the mutant c-Ki-ras allele in human tumor cells. *Proc Natl Acad Sci U S A* 1985; 82: 7575-9.
28. Wistuba II, Montellano FD, Milchgrub S, Virmani AK, Behrens C, Chen H, Ahmadian M, Nowak JA, Muller C, Minna JD, Gazdar AF. Deletions of chromosome 3p are frequent and early events in the pathogenesis of uterine cervical carcinoma. *Cancer Res* 1997; 57: 3154-8.
29. Wistuba II, Maitra A, Carrasco R, Tang M, Troncoso P, Minna JD, Gazdar AF. High resolution chromosome 3p, 8p, 9q and 22q allelotyping analysis in the pathogenesis of gallbladder carcinoma. *Br J Cancer* 2002; 87: 432-40.
30. Loeb LA. Mutator phenotype may be required for multistage carcinogenesis. *Cancer Res* 1991; 51: 3075-3079.
31. Jonason AS, Kunala S, Price GJ, Restifo RJ, Spinelli HM, Persing JA, Leffell DJ, Tarone RE, Brash DE. Frequent clones of p53-mutated keratinocytes in normal human skin. *Proc Natl Acad Sci U S A* 1996; 93: 14025-9.
32. Vanin K, Scurry J, Thorne H, Yuen K, Ramsay RG. Overexpression of wild-type p53 in lichen sclerosis adjacent to human papillomavirus-negative vulvar cancer. *J Invest Dermatol* 2002; 119: 1027-33.
33. Barrett MT, Sanchez CA, Prevo LJ, Wong DJ, Galipeau PC, Paulson TG, Rabinovitch PS, Reid BJ. Evolution of neoplastic cell lineages in Barrett oesophagus. *Nat Genet* 1999; 22: 106-9.
34. Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P. The IARC TP53 database: new online mutation analysis and recommendations to users. *Hum Mutat* 2002; 19: 607-14.
35. Levine AJ, Wu MC, Chang A, Silver A, Attiyeh EF, Lin J, Epstein CB. The spectrum of mutations at the p53 locus. Evidence for tissue-specific mutagenesis, selection of mutant alleles, and a "gain of function" phenotype. *Ann N Y Acad Sci* 1995; 768: 111-28.
36. Rideout WMD, Coetzee GA, Olumi AF, Jones PA. 5-Methylcytosine as an endogenous mutagen in the human LDL receptor and p53 genes. *Science* 1990; 249: 1288-90.
37. Campomenosi P, Conio M, Bogliolo M, Urbini S, Assereto P, Aprile A, Monti P, Aste H, Lapertosa G, Inga A, Abbondandolo A, Fronza G. p53 is frequently mutated in Barrett's metaplasia of the intestinal type. *Cancer Epidemiol Biomarkers Prev* 1996; 5: 559-65.
38. Hussain SP, Amstad P, Raja K, Ambs S, Nagashima M, Bennett WP, Shields PG, Ham AJ, Swenberg JA, Marrogi AJ, Harris CC. Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease. *Cancer Res* 2000; 60: 3333-7.
39. Apstein MD, Carey MC. Pathogenesis of cholesterol gallstones: a parsimonious hypothesis. *Eur J Clin Invest* 1996; 26: 343-52.
40. Ko CW, Lee SP. Gallstone formation. Local factors. *Gastroenterol Clin North Am* 1999; 28: 99-115.